113 related articles for article (PubMed ID: 6195513)
21. The use of a monoclonal antibody and of DNA recombinant technology for the localization of a poliovirus neutralization epitope in viral capsid polypeptide VP1.
Bruneau P; van der Werf S; Wychowski C; Siffert O; Girard M
Dev Biol Stand; 1984; 57():177-85. PubMed ID: 6084609
[TBL] [Abstract][Full Text] [Related]
22. Use of monoclonal antibodies prepared with Sabin vaccine viruses for the characterization of poliovirus strains isolated in Canada.
Wachmann B; Henning D; Armstrong R; Boucher DW; Contreras G; Furesz J
Dev Biol Stand; 1984; 57():141-9. PubMed ID: 6084605
[TBL] [Abstract][Full Text] [Related]
23. Antigenic structure of polioviruses of serotypes 1, 2 and 3.
Minor PD; Ferguson M; Evans DM; Almond JW; Icenogle JP
J Gen Virol; 1986 Jul; 67 ( Pt 7)():1283-91. PubMed ID: 2425046
[TBL] [Abstract][Full Text] [Related]
24. Neutralizing site of poliovirus.
Brown F
Nature; 1983 Aug 4-10; 304(5925):395-6. PubMed ID: 6192343
[No Abstract] [Full Text] [Related]
25. Principal and subsidiary antigenic sites of VP1 involved in the neutralization of poliovirus type 3.
Minor PD; Evans DM; Ferguson M; Schild GC; Westrop G; Almond JW
J Gen Virol; 1985 May; 66 ( Pt 5)():1159-65. PubMed ID: 2582084
[TBL] [Abstract][Full Text] [Related]
26. Characterization of human monoclonal antibodies that neutralize multiple poliovirus serotypes.
Puligedda RD; Kouiavskaia D; Al-Saleem FH; Kattala CD; Nabi U; Yaqoob H; Bhagavathula VS; Sharma R; Chumakov K; Dessain SK
Vaccine; 2017 Oct; 35(41):5455-5462. PubMed ID: 28343771
[TBL] [Abstract][Full Text] [Related]
27. Antibodies to poliovirus detected by immunoradiometric assay with a monoclonal antibody.
Spitz M; Fossati CA; Schild GC; Spitz L; Brasher M
J Virol Methods; 1982 Oct; 5(2):101-11. PubMed ID: 6296172
[TBL] [Abstract][Full Text] [Related]
28. Monoclonal antibodies to polioviruses. Production of specific monoclonal antibodies to the Sabin vaccine strains.
Osterhaus AD; van Wezel AL; van Steenis B; Drost GA; Hazendonk TG
Intervirology; 1981; 16(4):218-24. PubMed ID: 6177658
[TBL] [Abstract][Full Text] [Related]
29. Immunochemical studies of polioviruses: identification of immunoreactive virus capsid polypeptides.
Thorpe R; Minor PD; Mackay A; Schild GC; Spitz M
J Gen Virol; 1982 Dec; 63(2):487-92. PubMed ID: 6185628
[TBL] [Abstract][Full Text] [Related]
30. Antigenic sites of poliovirus type 3 eliciting IgA monoclonal antibodies in orally immunized mice.
Buttinelli G; Ruggeri FM; Marturano J; Novello F; Donati V; Fiore L
Virology; 2001 Mar; 281(2):265-71. PubMed ID: 11277698
[TBL] [Abstract][Full Text] [Related]
31. Reactivity of anti-peptide and anti-poliovirus type 3 monoclonal antibodies with synthetic peptides.
Ferguson M; Reed SE; Minor PD
J Gen Virol; 1986 Nov; 67 ( Pt 11)():2527-31. PubMed ID: 2431104
[TBL] [Abstract][Full Text] [Related]
32. A poliovirus neutralization epitope expressed on hybrid hepatitis B surface antigen particles.
Delpeyroux F; Chenciner N; Lim A; Malpièce Y; Blondel B; Crainic R; van der Werf S; Streeck RE
Science; 1986 Jul; 233(4762):472-5. PubMed ID: 2425433
[TBL] [Abstract][Full Text] [Related]
33. Neutralization epitopes on poliovirus type 3 particles: an analysis using monoclonal antibodies.
Ferguson M; Minor PD; Magrath DI; Qui YH; Spitz M; Schild GC
J Gen Virol; 1984 Jan; 65 ( Pt 1)():197-201. PubMed ID: 6198447
[TBL] [Abstract][Full Text] [Related]
34. A simple quantitative affinity capturing assay of poliovirus antigens and subviral particles by single-domain antibodies using magnetic beads.
Thys B; Saerens D; Schotte L; De Bleeser G; Muyldermans S; Hassanzadeh-Ghassabeh G; Rombaut B
J Virol Methods; 2011 May; 173(2):300-5. PubMed ID: 21371506
[TBL] [Abstract][Full Text] [Related]
35. Neutralization antigenic sites of poliovirus and peptide induction of neutralizing antibodies.
Emini EA; Wimmer E; Jameson BA; Bonin J; Diamond D
Ann Sclavo Collana Monogr; 1984; 1(2):139-46. PubMed ID: 6085885
[No Abstract] [Full Text] [Related]
36. Induction of neutralizing antibody in mice against poliovirus type II with monoclonal anti-idiotypic antibody.
Uytdehaag FG; Osterhaus AD
J Immunol; 1985 Feb; 134(2):1225-9. PubMed ID: 2981264
[TBL] [Abstract][Full Text] [Related]
37. Mapping of type 1 poliovirus neutralization epitopes.
Blondel B; Crainic R; Dufraisse G; Candréa A; Horaud F
Dev Biol Stand; 1985; 60():337-42. PubMed ID: 2412917
[TBL] [Abstract][Full Text] [Related]
38. Priming for and induction of anti-poliovirus neutralizing antibodies by synthetic peptides.
Emini EA; Jameson BA; Wimmer E
Nature; 1983 Aug 25-31; 304(5928):699-703. PubMed ID: 6310403
[TBL] [Abstract][Full Text] [Related]
39. Neutralization of poliovirus by antibody-mediated polymerization.
Brioen P; Dekegel D; Boeyé A
Virology; 1983 Jun; 127(2):463-8. PubMed ID: 6306919
[TBL] [Abstract][Full Text] [Related]
40. Studies of the antigenic variation in poliovirus type 1. Selection and analysis of variant strains with monoclonal antibodies by neutralization.
Thibodeau L; Lacroix M; Lecomte J; Fauvel M
Dev Biol Stand; 1984; 57():157-63. PubMed ID: 6084606
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
